NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Kalyani Steels Declares ₹10 Dividend; FY26 Net Profit Stable at ₹2,551 Million
Kalyani Steels has recommended a final dividend of ₹10 per share for FY 2025-26, representing a 200% payout on face value. For the full year, the company reported a marginal 0.8% increase in Profit After Tax to ₹2,551.37 million, even as revenue from operations dipped by 6.8% to ₹18,456.07 million. The fourth quarter saw a contraction in both top-line and bottom-line performance compared to the previous year. Additionally, the company announced key leadership changes, including the appointment of a new CFO and an Independent Director.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share of ₹5 each (200%) for FY 2025-26.Full-year Revenue from Operations decreased by 6.8% to ₹18,456.07 million from ₹19,819.04 million.Annual Profit After Tax (PAT) remained stable at ₹2,551.37 million versus ₹2,530.34 million in FY25.Q4 FY26 PAT declined to ₹710.25 million compared to ₹792.83 million in the same quarter last year.Appointed Mr. Bantu Upendra Kumar Patro as Chief Financial Officer effective May 9, 2026.
👀 கவனிக்க வேண்டியவை
While the consistent dividend provides a yield cushion, investors should be cautious about the declining revenue trend observed in FY26. Monitor the new management's strategy to address top-line growth and the impact of the ₹79.26 million exceptional labor code cost on future margins.
GKSL to Incorporate New Subsidiary for Bharuch Expansion and Appoints New CS
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the incorporation of a Wholly Owned Subsidiary (WOS) to expand its healthcare footprint into the Bharuch district of Gujarat. The company received shareholder approval via postal ballot to utilize IPO funds for this healthcare expansion. Additionally, the board approved a voluntary revision of financial statements under Section 131 of the Companies Act, indicating a correction in previous reporting. Ms. Vishakha Mahesh Phadke has been appointed as the new Company Secretary and Compliance Officer to strengthen corporate governance.
முக்கிய அம்சங்கள்
Approved incorporation of a Wholly Owned Subsidiary (WOS) with an initial nominal capital of ₹1,00,000.Expansion targeted at Bharuch district, adding to existing presence in Vadodara, Dahod, Ahmedabad, and Godhara.Shareholders passed a special resolution for interim utilization of IPO funds towards healthcare expansion.Board approved voluntary revision of Financial Statements and Board's report under Section 131 of the Companies Act.Appointment of Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer effective April 27, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view the expansion into Bharuch as a positive growth move, but should also seek clarity on the reasons for the voluntary revision of financial statements. Monitor the timeline for the new subsidiary's operational launch, expected by the end of H1 FY 2026-27.
GKSL Shareholders Approve Healthcare Expansion Funds and Financial Statement Revision
Gujarat Kidney and Super Speciality Limited (GKSL) has announced the successful passage of three key resolutions via postal ballot with near-unanimous support. Shareholders approved the interim utilization of funds for healthcare expansion, aligning with the company's IPO objectives. Notably, a special resolution for the voluntary revision of financial statements and the Board's report under Section 131 of the Companies Act was also passed. Additionally, the company confirmed the appointment of Mr. Dharmendra Bhaliya as the Secretarial Auditor for the 2025-26 fiscal year.
முக்கிய அம்சங்கள்
Resolution for healthcare expansion fund utilization passed with 100% of 5,68,46,254 valid votes in favor.Voluntary revision of Financial Statements and Board's Report approved with a 99.9998% majority.Total voter participation represented 72.10% of the company's total outstanding shares.Appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 was finalized with 99.9994% approval.
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific reasons for the voluntary revision of financial statements to ensure there are no underlying accounting or governance concerns. While the expansion plan is a positive growth indicator, the regulatory revision warrants a cautious approach.
Kalyani Steels CFO Bal Mukand Maheshwari Resigns After 13-Year Tenure
Kalyani Steels Limited has announced the resignation of its Chief Financial Officer (CFO), Mr. Bal Mukand Maheshwari, effective May 8, 2026. Mr. Maheshwari has served as the CFO for the past 13 years and cited personal reasons for his departure. The company has confirmed there are no other material reasons for the resignation. A smooth transition process is expected as the outgoing CFO has committed to extending full cooperation during the handover.
முக்கிய அம்சங்கள்
Mr. Bal Mukand Maheshwari resigns as CFO and Key Managerial Personnel (KMP) after 13 years of service.The resignation was officially tendered on April 16, 2026, with the relief date set for May 8, 2026.Departure is attributed to personal reasons with no other material concerns cited.The company must now identify a successor to lead its financial operations and strategy.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's announcement regarding a successor to ensure a qualified candidate is appointed to maintain financial stability. The long tenure of the outgoing CFO suggests a significant leadership transition that needs to be watched for any changes in financial strategy.
Kalyani Steels Completes Acquisition of 4.85% Stake in Clean Renewable Energy KK 1B
Kalyani Steels Limited (KSL) has successfully completed the acquisition of a 4.85% equity stake in Clean Renewable Energy KK 1B Private Limited, an SPV of Hero Rooftop Energy Private Limited. The company acquired 1,034,453 equity shares at a price of Rs. 28.37 per share, which includes a premium of Rs. 18.37 over the face value of Rs. 10. This strategic move is likely intended to meet captive power requirements or green energy mandates for its manufacturing operations. The transaction follows the initial proposal announced on March 27, 2026.
முக்கிய அம்சங்கள்
Acquisition of 1,034,453 equity shares in Clean Renewable Energy KK 1B Private Limited.Shares purchased at Rs. 10 face value plus a premium of Rs. 18.37 per share.The acquired stake represents 4.85% of the total paid-up equity capital of the SPV.The target entity is a Special Purpose Vehicle (SPV) of Hero Rooftop Energy Private Limited.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic step towards securing renewable energy, which could optimize long-term power costs and improve ESG ratings. No immediate impact on earnings is expected given the small stake size.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Kalyani Steels to Acquire 4.85% Stake in Clean Renewable Energy for Rs 2.93 Crore
Kalyani Steels Limited (KSL) has announced a strategic investment to acquire a 4.85% equity stake in Clean Renewable Energy KK 1B Private Limited, an SPV of Hero Rooftop Energy. The acquisition involves a cash consideration of Rs 2.93 crore for 1,034,453 equity shares. This move is designed to facilitate the sourcing of power through captive renewable energy sources under the group captive scheme. The target entity is a new venture incorporated in July 2024, specifically focused on electricity generation.
முக்கிய அம்சங்கள்
Acquisition of 1,034,453 equity shares representing a 4.85% stake in the target SPV.Total cash consideration for the transaction is Rs 2,93,50,000.Target entity is an SPV of Hero Rooftop Energy Private Limited focused on renewable power generation.Investment aims to optimize power costs and comply with group captive energy regulations.The target company was incorporated in July 2024 and reported no turnover for FY 2024-25.
👀 கவனிக்க வேண்டியவை
This is a strategic move to secure long-term renewable energy and optimize operational costs. While the investment amount is relatively small, it reflects a positive shift towards sustainable energy sourcing.
GKSL to Reallocate ₹3192.5 Lakhs IPO Funds and Revise Past Financial Statements
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a postal ballot seeking shareholder approval to significantly reallocate IPO proceeds. The company plans to divert ₹2510 lakhs originally intended for a Vadodara hospital toward a new multispeciality project in Bharuch and ₹682.50 lakhs toward a dialysis services collaboration. Furthermore, the company is voluntarily revising its financial statements and Board's reports for FY 2021-22, 2022-23, and 2023-24 following an NCLT order to ensure proper disclosure compliance.
முக்கிய அம்சங்கள்
Reallocation of ₹3010 lakhs from a proposed Vadodara hospital to a new multispeciality hospital project in Bharuch.Diversion of ₹682.50 lakhs from robotics equipment to establish dialysis services in collaboration with Lord’s Mark Industries Limited.Voluntary revision of financial statements and notes for three consecutive years (FY22 to FY24) as per NCLT order dated Feb 6, 2026.Utilization of ₹1262 lakhs from General Corporate Purposes to fund the revised healthcare expansion objects.Remote e-voting for these resolutions is scheduled from March 27, 2026, to April 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should closely examine the reasons for the geographic shift in expansion and the implications of the voluntary financial revisions on the company's historical performance data. Monitor the progress of the new Bharuch project as it replaces the original IPO objective.
GKSL Q2 FY26 Results: Revenue Up 2.5% to ₹9.64 Cr, PAT Declines 22% YoY
Gujarat Kidney And Super Speciality Limited (GKSL) reported a marginal 2.5% YoY revenue growth for Q2 FY26, reaching ₹9.64 crore. However, Profit After Tax (PAT) for the quarter dropped significantly by 22% to ₹2.30 crore compared to the same period last year, indicating margin pressure. On a half-yearly basis, the performance remains positive with revenue up 13% and PAT up 10% YoY. Investors should note a sharp increase in current borrowings to ₹12.71 crore and rising trade receivables, which may impact liquidity.
முக்கிய அம்சங்கள்
Q2 Revenue from operations stood at ₹964.26 Lacs, a slight increase from ₹941.00 Lacs YoY.Quarterly Net Profit declined to ₹230.12 Lacs from ₹295.73 Lacs in the previous year's quarter.Half-year (H1) PAT grew by 10.1% to ₹620.10 Lacs compared to ₹563.13 Lacs in H1 FY25.Current borrowings escalated sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025.Trade receivables increased to ₹1,862.59 Lacs as of September 2025, up from ₹1,279.91 Lacs in March 2025.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the significant rise in short-term debt and trade receivables, which could signal working capital stress. Monitor the company's ability to manage operational costs as quarterly margins have contracted despite stable revenue.
GKSL Acquires Parekhs Hospital Private Limited for ₹77 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has successfully executed the acquisition of a 100% stake in Parekhs Hospital Private Limited for ₹77 crore. The target entity, based in Ahmedabad, is a healthcare service provider with a steady revenue stream, reporting a turnover of ₹25.67 crore in FY 2024-25. This acquisition makes Parekhs Hospital a wholly-owned subsidiary of GKSL, aimed at strengthening the company's presence in the healthcare sector. The transaction was completed on March 22, 2026, through cash consideration.
முக்கிய அம்சங்கள்
Acquisition of 100% equity (2,55,000 shares) for a total cash consideration of ₹77 croreParekhs Hospital reported a turnover of ₹25.67 crore for FY 2024-25, showing stable performanceTarget company has a consistent financial track record with FY 2022-23 turnover at ₹24.06 croreStrategic expansion into the Ahmedabad healthcare market to diversify GKSL's business portfolioThe acquisition was completed on March 22, 2026, following an initial intimation in January 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant growth move, though the acquisition price of ₹77 crore for a ₹25.67 crore turnover business implies a high valuation multiple. Monitor the consolidated financial statements for improvements in margins and operational synergies post-integration.
GKSL Pays Rs 6.6 Lakh Penalty to BSE and NSE for Delayed Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges regarding a penalty payment of Rs 3,30,400 each to BSE and NSE, totaling Rs 6,60,800. The fine was imposed due to the company's failure to submit financial results within the prescribed timelines under Regulation 33 of SEBI LODR Regulations. The notices were received on March 17, 2026, and the company completed the payment via RTGS on March 21, 2026. While the monetary impact is limited, the delay in financial reporting is a negative signal regarding corporate governance and compliance discipline.
முக்கிய அம்சங்கள்
Total penalty of Rs 6,60,800 paid to stock exchanges (Rs 3,30,400 each to BSE and NSE).Penalty triggered by non-compliance with Regulation 33 for delayed submission of financial results.Notices were issued by the exchanges on March 17, 2026, and received late in the evening.Company confirmed the full payment of fines was completed on March 21, 2026, via RTGS.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution and monitor if the company improves its reporting discipline in future quarters. It is important to review the delayed financial results once published to check for any underlying operational issues.
GKSL Appoints New Auditors; H1 FY26 Revenue Grows to ₹21.09 Cr, PAT at ₹6.20 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26 to strengthen corporate governance. The company reported a steady financial performance for the half-year ended September 30, 2025, with revenue from operations reaching ₹2,109.25 Lacs, up from ₹1,867.05 Lacs in the previous year. Net profit for the same period increased to ₹620.10 Lacs compared to ₹563.13 Lacs YoY. Additionally, the board ratified previous meeting outcomes that were delayed in submission to the exchanges.
முக்கிய அம்சங்கள்
Revenue from operations grew by 13% YoY to ₹2,109.25 Lacs for the half-year ended September 30, 2025.Profit After Tax (PAT) for H1 FY26 stood at ₹620.10 Lacs, a growth from ₹563.13 Lacs in H1 FY25.Total Assets increased significantly to ₹6,694.02 Lacs as of September 2025 from ₹4,907.23 Lacs in March 2025.Appointment of new Internal and Secretarial Auditors with 7 and 5 years of professional experience respectively.Current borrowings rose sharply to ₹1,270.71 Lacs from ₹95.53 Lacs in March 2025, indicating potential expansion or working capital needs.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins given the rise in current borrowings and other expenses. The steady growth in PAT and strengthening of the audit team are positive signs for long-term governance.
GKSL Fined ₹3.30 Lakh by NSE and BSE for Delayed Q2 FY26 Financial Results
Gujarat Kidney And Super Speciality Limited (GKSL) has been penalized by both the National Stock Exchange (NSE) and BSE for non-compliance with SEBI Regulation 33. The exchanges have imposed a fine of ₹3,30,400 due to the company's failure to submit its financial results for the quarter ended September 30, 2025, within the prescribed timeline. While the company claims no significant impact on operations, the delay in reporting is a governance concern. The Board of Directors is expected to review the notice and provide further comments to the exchanges shortly.
முக்கிய அம்சங்கள்
NSE and BSE imposed a total fine of ₹3,30,400 including GST for regulatory non-compliance.The penalty pertains to the non-submission of financial results for the quarter ended September 30, 2025.Notices from both exchanges were received by the company on March 17, 2026.The company stated that the fine does not have a quantifiable impact on its financial or operational activities.The Board of Directors will shortly review the matter and provide official comments to the stock exchanges.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as delays in financial reporting can indicate internal administrative issues or poor corporate governance. Monitor the company's upcoming board comments to understand the reason behind the reporting delay.
GKSL Reports Q2 FY26 PAT of ₹2.30 Cr; Explains Delay in Financial Result Submission
Gujarat Kidney And Super Speciality Limited (GKSL) has released its delayed financial results for the quarter ended September 30, 2025, citing technical issues following its listing on December 30, 2025. For the quarter, the company reported revenue of ₹9.64 crore and a Profit After Tax (PAT) of ₹2.30 crore. On a half-yearly basis, revenue grew to ₹21.09 crore compared to ₹18.67 crore in the previous year, with PAT increasing to ₹6.20 crore from ₹5.63 crore. The company clarified that this was a first-time oversight due to being a newly listed entity.
முக்கிய அம்சங்கள்
Revenue from operations for Q2 FY26 stood at ₹964.26 Lacs, compared to ₹941.00 Lacs in the same period last year.Net Profit for the half-year ended September 30, 2025, rose to ₹620.10 Lacs from ₹563.13 Lacs YoY.Total Assets as of September 30, 2025, increased significantly to ₹6,694.02 Lacs from ₹4,907.23 Lacs in March 2025.Earnings Per Share (EPS) for the half-year ended September 2025 was reported at ₹1.22.The reporting delay was attributed to technical issues and the company's recent listing status as of December 30, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's future compliance to ensure timely disclosures, while noting the steady growth in half-yearly profitability. The current delay appears to be an administrative lapse rather than a fundamental business issue.
Kalyani Steels Settles SEBI Allegations for ₹2.80 Crore; CS Pays ₹95.55 Lakh
Kalyani Steels Limited and its Company Secretary have settled alleged regulatory violations with SEBI by paying a combined amount of approximately ₹3.76 crore. The allegations involved non-compliance with Related Party Transaction (RPT) approvals and disclosure norms under the SEBI LODR Regulations and SCRA. Specifically, the company paid ₹28,022,150, while the Company Secretary paid ₹9,555,000 to close the proceedings. This settlement allows the company to resolve historical compliance issues without admitting or denying the findings, ensuring no further legal overhang on these specific matters.
முக்கிய அம்சங்கள்
Kalyani Steels Limited paid a settlement amount of ₹2,80,22,150 to SEBI.Company Secretary Mrs. D.R. Puranik paid a separate settlement of ₹95,55,000.Allegations included violations of Regulation 23(2) and Clause 49 regarding Related Party Transactions and Audit Committee approvals.The settlement order (SO/JS/DP2025-26/7871-7873) was officially received on February 23, 2026.The company stated there are no further financial or operational implications beyond the paid amounts.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step in resolving past regulatory uncertainties, though it highlights previous lapses in governance. The financial impact is manageable and does not affect the core business operations.
GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.
முக்கிய அம்சங்கள்
Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.
👀 கவனிக்க வேண்டியவை
Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.
GKSL Receives NCLT Approval for Voluntary Revision of Financials and Board Reports (FY22-FY24)
Gujarat Kidney and Super Speciality Limited (GKSL) has received NCLT approval to voluntarily revise its Board Reports and Financial Statements for three financial years (FY22, FY23, and FY24). The revisions primarily address clerical errors, such as incorrect board meeting dates and director appointment timelines. Crucially, the company is correcting a miscategorization in FY24 where a business transfer amount was wrongly labeled as a 'Loan to directors.' Management has confirmed that these revisions have no impact on the company's financial performance, operations, or other activities.
முக்கிய அம்சங்கள்
NCLT Ahmedabad approved the voluntary revision of Board Reports and Financial Statements for FY 2021-22, 2022-23, and 2023-24.Correction of a miscategorized 'Loan to directors' in FY24 notes, which was actually related to a Business Transfer Agreement.Rectification of clerical errors regarding the company's conversion date from Private to Public (corrected to 24/11/2023).The company is directed to pay a nominal fee of ₹10,000 and file revised Form AOC-4 within 30 days.Management and auditors state there is no quantifiable monetary impact on the company's financial or operational status.
👀 கவனிக்க வேண்டியவை
Investors should view this as a corrective governance measure to ensure regulatory accuracy; no immediate action is required as the financials remain fundamentally unchanged. Monitor the filing of the revised reports to confirm the 'Loan to directors' miscategorization is officially resolved.
GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.
👀 கவனிக்க வேண்டியவை
Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.
GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.
முக்கிய அம்சங்கள்
Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 monthsStrategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolioTarget entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015
👀 கவனிக்க வேண்டியவை
Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.
Kalyani Steels Bound by Non-Compete Clause in Ferrous Casting Business
Kalyani Steels (KSL) has been identified as an affiliated entity bound by a non-compete restriction following a Shareholders Agreement (SHA) executed on February 2, 2026. The agreement involves Bharat Forge Limited (BFL), its subsidiaries, and PI Opportunities Fund I Scheme II. Under the terms, KSL is restricted from engaging in the ferrous casting business within India, as this segment is reserved for JS Auto Cast Foundry. While KSL can explore international opportunities in this niche, it may only do so if the JS Auto Board first rejects the opportunity.
முக்கிய அம்சங்கள்
KSL is now bound by non-compete and non-solicitation restrictions for ferrous casting in India.The restriction stems from an SHA signed on February 2, 2026, between BFL Group and an external investor.Domestic ferrous casting business is now centralized under JS Auto Cast Foundry India Private Limited.KSL can only pursue international casting opportunities if they are rejected by the JS Auto Board.The company confirmed there is no impact on its management or control.
👀 கவனிக்க வேண்டியவை
Investors should view this as a formalization of business boundaries within the Kalyani Group. No immediate impact on KSL's core specialty steel operations is expected, though it limits future diversification into domestic casting.
Kalyani Steels Q3 FY26 PAT Rises 10.7% YoY to ₹61.3 Cr Despite Revenue Dip
Kalyani Steels reported a standalone Profit After Tax (PAT) of ₹613.18 million for the quarter ended December 31, 2025, marking a 10.7% increase from ₹553.89 million in the corresponding quarter last year. Revenue from operations declined by 4.5% YoY to ₹4,623.76 million, though it showed a marginal sequential growth from Q2 FY26. The company's bottom line was supported by a significant reduction in total expenses, which fell by 8.3% YoY. Results were slightly impacted by a one-time exceptional charge of ₹67.34 million related to the consolidation of new Labour Codes by the Government of India.
முக்கிய அம்சங்கள்
Standalone PAT grew 10.7% YoY to ₹613.18 million in Q3 FY26.Revenue from operations decreased 4.5% YoY to ₹4,623.76 million from ₹4,840.05 million.Total expenses reduced significantly to ₹3,870.13 million from ₹4,219.18 million in the previous year's quarter.Exceptional one-time expense of ₹67.34 million recognized for incremental impact of new Labour Codes.Consolidated Earnings Per Share (EPS) for the quarter stood at ₹14.19, up from ₹12.93 YoY.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to expand margins through cost control despite a slight contraction in top-line revenue. The stock remains a solid hold for those looking at the specialty steel segment, with a focus on how volume growth recovers in future quarters.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
